GlobeNewswire Inc | Mar 3, 2021 06:00PM EST

March 03, 2021

Montrouge, France, March 3, 2021

DBV Technologies Announces Date Change for Reporting Full Year 2020 Financial Results

DBV Technologies (Euronext: DBV ISIN: FR0010417345 Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that the Company has changed the date of its previously scheduled financial results conference call and live audio webcast. The Company will now report its full year 2020 financial results and provide a general corporate update on Thursday, March 11th at 5:00pm ET (11:00pm CET).

The conference call is accessible via the below teleconferencing numbers, followed by the reference ID: 50114481.

-- United States: (866) 866-1333 -- Canada: (866) 215-5508 -- United Kingdom: 0808 238 9578 -- France: 0805 102 604

A live webcast of the call will be available on the Investors & Media section of the Companys website: https://www.dbv-technologies.com/investor-relations/. A replay of the presentation will also be available on DBVs website after the event.

About DBV TechnologiesDBV Technologies is developing Viaskin, an investigational proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT, DBVs method of delivering biologically active compounds to the immune system through intact skin. With this new class of non-invasive product candidates, the Company is dedicated to safely transforming the care of food allergic patients. DBVs food allergies programs include ongoing clinical trials of Viaskin Peanut. DBV Technologies has global headquarters in Montrouge, France and offices in Bagneux, France, and North American operations in Summit, NJ and New York, NY. The Companys ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), and the Companys ADSs (each representing one-half of one ordinary share) are traded on the Nasdaq Global Select Market (Ticker: DBVT).

Investor Contact Anne PollakDBV Technologies+1 857-529-2363anne.pollak@dbv-technologies.com

Media ContactAngela MarcucciDBV Technologies+1646-842-2393angela.marcucci@dbv-technologies.com

Attachment

-- PDF Version